Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset

Boyer, Laurent; Chéreau, Isabelle; Aouizerate, Bruno; Berna, Fabrice; Blanc, Olivier; Brunel, Lionel; Bulzacka, E.; Capdevielle, Delphine; Chéreau-Boudet, I.; Chesnoy-Servanin, G.; Danion, Jean-Marie; d’Amato, Thierry; Deloge, A.; Delorme, C.; Denizot, H.; Pradier, M; Dorey, Jean‐Michel; Dubertret, Caroline; Dubreucq, Julien; Faget, Catherine; Fluttaz, C.; Fond, Guillaume; Fonteneau, S.; Gabayet, Franck; Giraud-Baro, É.; Hardy-Baylé, Marie-Christine; Lacelle, D.; Lançon, Christophe; Laouamri, H.; Leboyer, Marion; Gloahec, T. Le; Strat, Yann Le; Llorca, Pierre‐Michel; Mallet, J.; Metairie, E.; Misdrahi, D.; Offerlin-Meyer, I.; Passerieux, C.; Peri, P.; Pires, S.; Portalier, C.; Rey, R.; Román, C.; Sebilleau, M.; Schandrin, A.; Schürhoff, Franck; Tessier, A.; Tronche, Anne-Marie; Urbach, M.; Vaillant, F.; Véhier, A.; Vidailhet, P.; Vilain, J.; Vilà, E.; Yazbek, Hanan; Zinetti-Bertschy, A.

doi:10.1016/j.schres.2015.10.040

Cited by 42 publications

(29 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the study design did not permit changes in antipsychotic medication in the 4 weeks prior to the initial assessment, it is likely that some of these patients had the chronic akathisia subtype. Patients on combination SGAs (second-generation antipsychotic) had a higher risk of akathisia than those prescribed a SGA with a FGA (first generation antipsychotic) (34.2% vs. 14.7%) [ 19 ]. Moreover, patients on more than one SGA had a 3-fold increased risk of akathisia compared to SGA monotherapy (34.2% vs. 10.9) [ 19 ].…”

Section: Epidemiologymentioning

confidence: 99%

“…Patients on combination SGAs (second-generation antipsychotic) had a higher risk of akathisia than those prescribed a SGA with a FGA (first generation antipsychotic) (34.2% vs. 14.7%) [ 19 ]. Moreover, patients on more than one SGA had a 3-fold increased risk of akathisia compared to SGA monotherapy (34.2% vs. 10.9) [ 19 ]. The rate of akathisia reported in this study was consistent with previous estimates in the literature.…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges

Salem

Nagpal

Pigott

et al. 2017

View full text Add to dashboard Cite

Background: Akathisia continues to be a significant challenge in current neurological and psychiatric practice. Prompt and accurate detection is often difficult and there is a lack of consensus concerning the neurobiological basis of akathisia. No definitive treatment has been established for akathisia despite numerous preclinical and clinical studies.Method:We reviewed antipsychotic-induced akathisia including its clinical presentation, proposed underlying pathophysiology, current and under investigation therapeutic strategies.Conclusion:Despite the initial promise that second generation antipsychotics would be devoid of akathisia effects, this has not been confirmed. Currently, there are limited therapeutic options for the clinical practice and the evidence supporting the most widely used treatments (beta blockers, anticholinergic drugs) is still absent or inconsistent.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges

Salem

Nagpal

Pigott

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Overall, SGA including clozapine, olanzapine and risperidone have been found to be associated with fewer EPS than haloperidol (FGA). However, clinical trials are not representative of "real world" schizophrenia, as many patients are administered antipsychotic polytherapy combined with other psychotropic drugs (antidepressant, anxiolytic, anticholinergic) with various degrees of adherence and drug comorbidities, especially daily tobacco smoking that may impact antipsychotic blood levels 11,[18][19][20] .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics

Misdrahi¹,

Tessier²,

Daubigney³

et al. 2019

J. Clin. Psychiatry

View full text Add to dashboard Cite

Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing. Objectives: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicentric sample of stabilized patients with schizophrenia. Method: Between 2010 and 2016,patients suffering from schizophrenia (DSM-IV-TR) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day long standardized evaluation. The Simpson and Angus Scale and the Abnormal Involuntary Movement Scale were used to assess respectively Drug-Induced Parkinsonism (DIP) and Tardive Dyskinesia (TD). Results: The overall prevalence of DIP and TD was respectively 13.2% and 8.3% in our community-dwelling sample of 674 patients. DIP was associated with negative symptoms (PANSS sub-score) (aOR = 1.102, p<.001), First Generation Antipsychotic (FGA) (aOR = 2.038, p=.047) and anticholinergic drug administration (aOR = 2.103, p=.017) independently of sex, age, disorganization, and antipsychotic polytherapy. TD was associated with PANSS disorganized factor (aOR = 1.103, p=.049) independently of sex, age, negative symptoms, excitation, first-generation antipsychotic, benzodiazepine and anticholinergic drug administration. Conclusion: Our results indicate the high prevalence of EPS in a non-selected communitydwelling clinically stable sample of outpatients with schizophrenia. EPS should be systematically evaluated, especially in case of negative symptoms and disorganization or cognitive alteration in the monitoring of antipsychotic treatment. Monotherapy with an SGA should be preferentially initiated for patients with these sides-effects.

show abstract

“…46,47 It appears that this work is the first to describe a statistically significant relationship between age and the development of akathisia with the use of DRBAs. To date, prospective cohort studies of community-dwelling patients with schizophrenia 48 and literature reviews exploring the epidemiology of drug-induced akathisia 49,50 have not been able to draw firm conclusions regarding age as a risk factor for akathisia. It is possible that including a wider age group of patients in the present study population (range, 14–96 years old) allowed for differences in akathisia risk to emerge.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy

Schwartz¹,

Ruekert²,

Myers³

et al. 2019

J Clin Psychopharmacol

View full text Add to dashboard Cite

show abstract

Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset

Cited by 42 publications

References 43 publications

Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges

Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges

Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics

Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy

Contact Info

Product

Resources

About